Can you screen targets without an experimental crystal structure?

Yes, Creative Biolabs utilizes high-fidelity homology modeling and AI-driven structure prediction to facilitate screening against targets lacking known structures.

How do you ensure the synthetic feasibility of generated molecules?

Our models are constrained by synthetic accessibility (SA) scores and reviewed by senior chemists to ensure all designs can be efficiently synthesized.

Do you offer fragment-based screening?

Yes, we provide fragment screening using NMR and X-ray crystallography as a complementary approach to traditional HTS for identifying novel binding pockets.

Integrated Small Molecule Hit Discovery Services

Creative Biolabs bridges the gap between target identification and preclinical delivery by providing high-potency chemical entities optimized for synthetic feasibility, metabolic stability, and drug-likeness. By integrating structure-based design with generative chemistry, we resolve the "affinity vs. safety" dilemma early in the pipeline. Our platform utilizes advanced computational modeling to predict physiological behavior, reducing reliance on iterative laboratory trials and providing the technical depth required to navigate challenging chemical spaces for enzymes or membrane-bound receptors.

Background Featured Services Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us

Scientific Foundations: Introduction to Modern Hit Discovery Strategies

Small molecule discovery has shifted to a rational, AI-driven discipline, integrating knowledge graphs and flexible receptor modeling to navigate multi-billion compound libraries. By leveraging generative algorithms and AI-accelerated docking, researchers can move beyond traditional screening constraints to address "undruggable" targets. This gold-standard approach prioritizes binding affinity and ADMET properties from inception, seamlessly bridging in silico prediction with in vitro validation. This integration reduces development attrition and late-stage failures, significantly accelerating therapeutic progress across the biotechnology sector.

Comprehensive Discovery Solutions

Creative Biolabs offers an expansive suite of discovery modalities tailored to the specific needs of modern biotechnology. Our offerings are categorized to support diverse therapeutic strategies:

Small Molecule HTS Screening Module

Creative Biolabs provides a high-throughput small molecule HTS screening module, quantifying binding kinetics and functional potency. Utilizing vast chemical libraries, we accelerate lead discovery and structure-activity relationship (SAR) analysis.

Learn More →

Small Molecule Virtual Screening Module

Creative Biolabs provides small molecule virtual screening module services, integrating deep learning and high-resolution docking. We navigate vast chemical spaces to identify potent hits, accelerating the genomic-to-lead validation process.

Learn More →

Fragment based Small Molecule Drug Discovery Module

Creative Biolabs provides fragment-based small molecule drug discovery module services, utilizing NMR and X-ray crystallography to identify low-molecular-weight hits. We evaluate binding modes to accelerate fragment-to-lead optimization.

Learn More →

Small Molecule Hit Profiling & Prioritization Module

Creative Biolabs provides a small molecule hit profiling and prioritization module, integrating binding kinetics and ADMET modeling. We resolve physicochemical liabilities to identify stable and high-potency leads for lead optimization.

Learn More →

Panels

Creative Biolabs provides panel screening services for immuno-oncology drug discovery, quantifying checkpoint modulation and immune cell activation. We utilize high-throughput assays to validate antibody efficacy and accelerate lead candidate selection.

Learn More →

Targeted Protein Degradation

Creative Biolabs provides a comprehensive targeted protein degradation service, leveraging the ubiquitin-proteasome system to resolve undruggable targets. We quantify ternary complex formation and E3 ligase recruitment to facilitate lead optimization.

Learn More →

Workflow

To ensure transparency and scientific rigor, Creative Biolabs follows a comprehensive and data-driven workflow:

Publication

This critical review evaluates the role of artificial intelligence in small-molecule drug discovery, emphasizing AI as a complementary tool rather than a replacement for traditional methods. It covers the evolution from early QSAR to modern deep learning, generative models, and agentic AI, with applications in target identification, virtual screening, lead optimization, and ADMET prediction. The review analyzes real-world outcomes, including successes like baricitinib (repurposed) and rentosertib (Phase IIa), as well as failures such as DSP-1181 (discontinued). Key challenges, data quality, interpretability, regulatory acceptance, and emerging trends like foundation models and autonomous systems are discussed, offering practical guidance for integration.

Why Choose Us?

Creative Biolabs leads the generative chemistry revolution by integrating flexible receptor modeling and biomedical knowledge graphs to discover high-affinity hits, achieving success rates up to 44% on challenging targets like ion channels and E3 ligases. Our multidisciplinary team ensures every hit is potent, synthetically accessible, and pharmacologically relevant. Adhering to data principles, we combine ultra-large library navigation with de novo design to minimize preclinical risk. This integrated approach significantly increases the probability of identifying successful lead scaffolds where traditional, static docking models fail.

FAQs

Customer Review

Related Services

Venom Peptides Synthesis Service

Creative Biolabs provides custom and recombinant venom peptide synthesis, specializing in disulfide-rich scaffolds and complex modifications (cyclization, glycosylation). We deliver high-throughput peptide libraries to accelerate therapeutic discovery for chronic pain and oncology.

Learn More →

Nuclear Receptor Assay Services

Creative Biolabs provides nuclear receptor assays, quantifying ligand binding and transcriptional activity via reporter gene platforms. We offer high-throughput screening and cell-based signaling assays to optimize potency and specificity for lead candidates.

Learn More →

How to Contact Creative Biolabs

Creative Biolabs offers a world-class, integrated approach to small molecule hit discovery, merging the latest in generative AI with decades of medicinal chemistry expertise. From target validation with high-quality probes to the delivery of optimized preclinical leads, we provide the tools needed to turn biological breakthroughs into therapeutic realities.